BiVictriX Therapeutics PLC (GB:BVX) has released an update.
BiVictriX Therapeutics PLC, a UK-based drug discovery firm, announced that all resolutions proposed at their Annual General Meeting were passed with overwhelming shareholder support. The company, known for its novel bispecific antibody drug conjugates aimed at targeting cancer with greater efficacy and reduced toxicity, also confirmed the availability of proxy vote details on their website. BiVictriX continues to develop a proprietary pipeline of cancer therapeutics designed to target a range of cancer types with high precision.
For further insights into GB:BVX stock, check out TipRanks’ Stock Analysis page.
